TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07749768: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis

Sponsor: Ono Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07749768 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07749768 Rescue Dossier →